May. 12, 2021—Anthony Fauci, MD, chief medical adviser to President Joe Biden’s administration and director of the National Institute of Allergy and Infectious Diseases (NIAID), recently met virtually with students of Vanderbilt University School of Medicine’s Master of Public Health (MPH) program to answer questions about lessons learned during the pandemic and to share career advice.
May. 6, 2021—A protein implicated in neurodegenerative diseases including amyotrophic lateral sclerosis prevents the activation of an innate immune response that leads to cell death, Vanderbilt researchers have discovered.
Mar. 25, 2021—An FDA-approved medication enhances the function of T regulatory cells (Treg), a class of immune cells that restrains the immune response, Vanderbilt investigators have discovered.
Dec. 10, 2020—Vanderbilt University Medical Center investigators have identified a key molecular player in the early events of the inflammatory response to infection. The findings suggest new therapeutic possibilities for enhancing the inflammatory response to protect against pathogens and for blocking inflammation gone awry in diseases like arthritis and atherosclerosis.
Nov. 2, 2020—Vanderbilt University Medical Center has begun recruiting up to 250 participants for a Phase 3 clinical trial testing an investigational COVID-19 vaccine candidate developed by the Janssen Pharmaceutical Companies of Johnson & Johnson.